NCPA appoints Sharlea Leatherwood new president
ALEXANDRIA, Va. The National Community Pharmacists Association Foundation has appointed a new president.
Sharlea Leatherwood, who became the first woman officer of NCPA in 1989, was appointed president of the NCPA at the association’s 109th Annual Convention and Trade Exposition two weeks ago.
“Sharlea has been a dedicated community pharmacist and member of NCPA and the NCPA Foundationfor over 20 years,” said Bruce Roberts, RPh, executive vice president and chief executive officer of NCPA. “We are pleased to have her on board as president and look forward to her work to expand the foundation, increase its philanthropy, and increase its support of community pharmacists.”
Leatherwood has held several positions at the NCPA. In addition to becoming NCPA’s first woman officer in 1989 and its first woman president in 2003, Leatherwood is a member on the NCPA Foundation Board of Trustees, and was a founding board member of several programs enacted by the organization.
Leatherwood is succeeding immediate past NCPA Foundation president Charles West, who will remain as an NCPA Foundation board trustee. West has served as the NCPA Foundation President since 2000 and previously served as NCPA executive vice president from 1984-1996.
Sandoz completes $10 million expansion of N.C. facility
WILSON, N.C. Sandoz recently completed the major phase of its Wilson, North Carolina expansion when over 50 employees moved into a new 30,000 square foot building.
Over 65 new jobs are expected to be created in Wilson as a result of the $10 million expansion. The positions will be filled by pharmaceutical scientists and analytical chemists and will bring the total of employees at the site to almost 480.
“The new laboratories present an excellent workplace and opportunity for top scientists to help us continue to growth in the U.S.,” said Bernhard Hampl, president and chief executive officer of Sandoz. “The new products developed at the site will be the basis for the future growth of the Wilson site.”
Pfizer, Taisho sign letter of intent over schizophrenia drug candidate
TOKYO and NEW YORK Taisho Pharmaceuticals and Pfizer have concluded on a letter of intent with regard to Taisho’s new drug candidate for schizophrenia, TS-032.
The drug is currently in the pre-clinical stage and the letter of intent relates to a proposed license agreement regarding rights for development and commercialization.
Through the agreement, Taisho will grant exclusive development and commercialization rights outside Japan for the drug to Pfizer. Once the agreement is signed, Taisho will receive an initial payment of $22 million as well as milestone and royalties linked to the development and sales of the drug.